Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats

Journal of Pharmacy and Pharmacology

Volumn 52, Issue 12, 2000, Pages 1473-1481

  Daniel, W A ^a   Syrek, M ^a   Haduch, A ^a   Wojcikowski J ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DRUG METABOLITE; IMIPRAMINE; N DESMETHYLPERAZINE; NEUROLEPTIC AGENT; PERAZINE; PHENOTHIAZINE DERIVATIVE; PROMAZINE; SULFOXIDE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG MIXTURE; DRUG OXIDATION; INCUBATION TIME; LIVER MICROSOME; LONG TERM EXPOSURE; MALE; NONHUMAN; RAT; STEADY STATE;

AMITRIPTYLINE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BRAIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; IMIPRAMINE; MALE; METHYLATION; MICROSOMES, LIVER; OXIDATION-REDUCTION; PERAZINE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 0034534454     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357001777685     Document Type: Article

References (39)

1. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses
2. Desipramine hydroxylation: Effect of antipsychotic drugs
3. Urinary metabolites of 10-[3′-(4-methylpiperazinyl)-propyl]-phenothiazine (perazine) in psychiatric patients - I. Isolation, identification and determination of metabolites
4. Accumulation and elimination of a novel metabolite during chronic administration of the phenothiazine drug perazine to rats
5. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data
6. Single-dose kinetics of the neuroleptic drug perazine in psychotic patients
7. Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics
8. Role of P4502D6, the targed of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine
9. Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after one and six half-life repeated administrations to rats
10. Disposition of perphenazine is related to the polymorphic hydroxylation in human beings
11. Pharmacokinetic interaction between imipramine and antidepressant neuroleptics in rats
12. The effect of neuroleptics on imipramine demethylation in rat liver microsomes and imipramine and desipramine level in the rat brain
13. Lysosomal trapping as an important mechanism involved in cellular distribution of perazine and in the pharmacokinetic interaction with antidepressants
14. Cerebral pharmacokinetics of imipramine after single and multiple dosages
15. Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine
16. Pharmacokinetics and metabolism of thioridazine during coadministration of tricyclic antidepressants
17. Molecular genetics of the P-450 super-family
18. Pharmacokinetic interaction between neuroleptics and tricyclic antidepressants in the rat
19. Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man
20. Pharmacokinetic interaction between amitriptyline and neuroleptics
21. Urinary metabolites of 10-[3′-(4̃-methylpiperazinyl)-propyl]-phenothiazine (perazine) in psychiatric patients - II. Individual metabolite patterns and their changes in the course of treatment
22. Pharmacologic treatment of schizoaffective disorder
23. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man
24. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human 2D6
25. Cobalt as a modifier of microsomal monooxygenases in mice
26. Interaction of chlorpromazine and nortriptyline in patients with schizophrenia
27. Protein measurement with the Folin fenol reagent
28. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia
29. The new polypharmacy in psychiatry. Clinical practice and clinical research part company
30. Combined treatment strategies in psychiatry
31. Neuroleptic effect on desipramine steady-state plasma concentration
32. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
33. A new method for simultaneous purification of cytochrome b and NADPH-cytochrome reductase from rat liver microsomes
34. Monitoring of serum bioactivity levels of perazine and its metabolites by radioreceptor assay
35. Hydroxylation of desmethylimipramine: Dependence on debrisoquine hydroxylation phenotype
36. Inhibition of desipramine 2-hydroxylation by quinidine and quinine
37. Promazine Pharmacokinetics during concurrent treatment with tricyclic antidepressants
38. Interaction between amitriptyline and phenothiazine in man: Effect on plasma concentration of amitriptyline and its metabolite nortriptyline and the correlation with clinical response
39. Pharmacokinetics of neuroleptics